Combination chemotherapy for metastatic or recurrent adenocarcinoma of the cervix.
- 1 October 1987
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 5 (10) , 1621-1623
- https://doi.org/10.1200/jco.1987.5.10.1621
Abstract
Twenty-four patients with recurrent or widespread adenocarcinoma of the cervix were treated with combination chemotherapy. The drugs used were 5-fluorouracil (5-FU) (500 to 800 mg/m2), doxorubicin (40 to 50 mg/m2), and cisplatin (50 to 60 mg/m2). The chemotherapy was administered as a 76-hour continuous infusion via a silastic central venous catheter and repeated every 28 days. The total response rate was 42% (25% complete and 17% partial). Median duration of response was 7 months. Areas of response were usually lung and lymph node metastases. Toxicity, mainly neutropenia, was acceptable. All patients relapsed. This combination chemotherapy results in a modest response rate for a malignancy about which there is little information regarding the treatment of disseminated disease. Future studies should determine the activity of this combination administered in a bolus fashion.This publication has 7 references indexed in Scilit:
- PHASE-II TRIALS OF CISPLATIN AND PIPERAZINEDIONE AS SINGLE AGENTS IN THE TREATMENT OF ADVANCED OR RECURRENT NON-SQUAMOUS CELL-CARCINOMA OF THE CERVIX - A GYNECOLOGIC ONCOLOGY GROUP-STUDY1986
- ICRF-159 (Razoxane) in Patients with Advanced Nonsquamous Cell Carcinoma of the Cervix A Gynecologic Oncology Group StudyAmerican Journal of Clinical Oncology, 1986
- Adenocarcinoma of the uterine cervixCancer, 1986
- ADENOCARCINOMA OF THE UTERINE CERVIX - A STUDY OF 73 CASES1985
- Adenocarcinoma of the uterine cervix. Prognosis and prognostic significance of histologyCancer, 1984
- Reduction of Doxorubicin Cardiotoxicity by Prolonged Continuous Intravenous InfusionAnnals of Internal Medicine, 1982
- CLINICAL PHASE I-II STUDY OF CIS-DICHLORODIAMMINEPLATINUM(II) GIVEN BY CONTINUOUS IV INFUSION1978